Marion C. Jones

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Prospective evaluation of nontuberculous mycobacteria disease in cystic fibrosis: The design of the PREDICT study”.

Prospective evaluation of nontuberculous mycobacteria disease in cystic fibrosis: The design of the PREDICT study

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.08.007

N/A

0.488DataRank · unranked

6 citations

Silvia M. Caceres, Katie R. Poch, N. Rysavy, Valerie K. Lovell, Emily Armantrout +14 more

Urine lipoarabinomannan as a marker for low-risk of NTM infection in the CF airway

Journal of Cystic Fibrosis(2020)10.1016/j.jcf.2020.06.016

N/A

0DataRank · unranked

19 citations

Anita G. Amin, Barbara Graham, Stacey L. Martiniano, Silvia M. Caceres, Katie R. Poch +6 more

Prospective Analysis of urINe LAM to Eliminate NTM Sputum Screening (PAINLESS) study: Rationale and trial design for testing urine lipoarabinomannan as a marker of NTM lung infection in cystic fibrosis

medRxiv(2024)10.1101/2024.08.08.24311698

N/A

0DataRank · unranked

0 citations

Emily Armantrout, Katie R. Poch, Silvia M. Caceres, Valerie K. Lovell, Marion C. Jones +9 more

Prospective Analysis of urINe LAM to Eliminate NTM Sputum Screening (PAINLESS) study: Rationale and trial design for testing urine lipoarabinomannan as a marker of NTM lung infection in cystic fibrosis

PLoS ONE(2025)10.1371/journal.pone.0309191

N/A

0DataRank · unranked

0 citations

Emily Armantrout, Katie R. Poch, Silvia M. Caceres, Valerie K. Lovell, Marion C. Jones +9 more